Literature DB >> 2897206

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

R R Weber1, C E McCoy, J A Ziemniak, E D Frederickson, L I Goldberg, M B Murphy.   

Abstract

1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min. The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1. 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897206      PMCID: PMC1386609          DOI: 10.1111/j.1365-2125.1988.tb03276.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.

Authors:  H O Ventura; F H Messerli; E D Frohlich; I Kobrin; W Oigman; F G Dunn; R M Carey
Journal:  Circulation       Date:  1984-06       Impact factor: 29.690

2.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

3.  Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

Authors:  R A Hahn; J R Wardell; H M Sarau; P T Ridley
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

4.  The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics.

Authors:  N L Allison; J W Dubb; J A Ziemniak; F Alexander; R M Stote
Journal:  Clin Pharmacol Ther       Date:  1987-03       Impact factor: 6.875

5.  A new oral renal vasodilator, fenoldopam.

Authors:  R M Stote; J W Dubb; R G Familiar; B B Erb; F Alexander
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

6.  Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detection.

Authors:  V K Boppana; F C Heineman; R K Lynn; W C Randolph; J A Ziemniak
Journal:  J Chromatogr       Date:  1984-12-28

7.  Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.

Authors:  R M Carey; R M Stote; J W Dubb; L H Townsend; C E Rose; D L Kaiser
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.

Authors:  A Hughes; S Thom; G Martin; D Redman; S Hasan; P Sever
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

  8 in total
  16 in total

1.  Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.

Authors:  D C Borcherding; W Tong; E R Hugo; D F Barnard; S Fox; K LaSance; E Shaughnessy; N Ben-Jonathan
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

2.  Exercise activates vagal induction of dopamine and attenuates systemic inflammation.

Authors:  Guilherme Shimojo; Biju Joseph; Roshan Shah; Fernanda M Consolim-Colombo; Kátia De Angelis; Luis Ulloa
Journal:  Brain Behav Immun       Date:  2018-10-27       Impact factor: 7.217

3.  Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs.

Authors:  C A Bloom; M A Labato; S Hazarika; M H Court
Journal:  J Vet Pharmacol Ther       Date:  2011-07-06       Impact factor: 1.786

4.  A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 6.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

7.  Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

8.  Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease.

Authors:  Valentina Rovella; Michele Ferrannini; Manfredi Tesauro; Giulia Marrone; Andrea Busca; Roberto Sorge; Simone Manca di Villahermosa; Maurizio Casasco; Nicola Di Daniele; Annalisa Noce
Journal:  J Nephrol       Date:  2018-05-15       Impact factor: 3.902

Review 9.  Treatment of acute severe hypertension: current and newer agents.

Authors:  Joseph Varon
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.

Authors:  S Aronson; L I Goldberg; S Roth; D Glock; J Moss; M F Roizen
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.